IndiaFilingsIndiaFilings
India FlagRegister India Company
UAE FlagRegister UAE Company
USA FlagRegister USA Company

MORPHEUS SRIRAM INTERNATIONAL IVF CENTRE LLP

LLPIN : AAF-9184|ROC: RoC-MumbaiActive
Last Updated On : 30-01-2023
LLPINAAF-9184
LLP NameMORPHEUS SRIRAM INTERNATIONAL IVF CENTRE LLP
Number of Partners2
Number of Designated Partners2
ROC CodeRoC-Mumbai
Date of Incorporation14-03-2016
Registered AddressMittal Tower, B-Wing, 16th Floor, 210, Nariman Point, Mumbai Mumbai City Maharashtra 400021
Email ID[email protected]
Total Obligation of Contribution15,00,000
Main division of business activity to be carried out in India74
Description of main divisionOther Business Activities
Date of last financial year end for Statement of Accounts and Solvency2022-03-31
Date of last financial year end for Annual Return filed31-03-2022
LLP StatusActive

Directors / Signatory Details

DIN / PANNameBegin Date
03142838KAVITHA CHALASANI14-03-2016
06839649WASEEM WAHEED KHAN27-09-2021
MORPHEUS SRIRAM INTERNATIONAL IVF CENTRE LLP is a Limited Liability Partnership (LLP) governed by the LLP Act, 2008. Registered under the Registrar of Companies RoC-Mumbai, it operates as a non-government entity. According to the Ministry of Corporate Affairs (MCA), this LLP was incorporated on 14-03-2016 and last updated on 30-01-2023. Its LLP Identification Number (LLPIN) is , and the registration number is . Currently, its eFiling status is listed as “Active” as per MCA records.
From a financial standpoint, MORPHEUS SRIRAM INTERNATIONAL IVF CENTRE LLP has a total contribution of INR 15,00,000. Details of the latest financial filings, such as the Statement of Accounts and Solvency or Annual Returns, are unavailable, indicating limited publicly disclosed financial data.
The registered office address is Mittal Tower, B-Wing, 16th Floor, 210, Nariman Point, Mumbai Mumbai City Maharashtra 400021. Correspondence or inquiries may be sent to the official email address, [email protected].
For those interested in further details, below are some frequently asked questions: